Actavia Life Sciences (Actavia Life Sciences) Risk Assessment

View and export this data going back to 2014. Start your Free Trial

What is Actavia Life Sciences Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Actavia Life Sciences is: No Data: Cannot be evaluated.

Competitive Comparison of Actavia Life Sciences's Risk Assessment

For the Biotechnology subindustry, Actavia Life Sciences's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actavia Life Sciences's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actavia Life Sciences's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Actavia Life Sciences's Risk Assessment falls into.

Actavia Life Sciences (OTCPK:RASP) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Actavia Life Sciences Risk Assessment Related Terms

Thank you for viewing the detailed overview of Actavia Life Sciences's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Actavia Life Sciences (Actavia Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actavia Life Sciences Inc (OTCPK:RASP) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Lexington Avenue, Suite 2525, New York, NY, USA, 10170

Website

https://www.rasna.com

Rasna Therapeutics Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.

Actavia Life Sciences (Actavia Life Sciences) Headlines

No Headlines